New cancer drug trial halted early – what we know
NCT ID NCT05252390
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NUV-868 (an experimental oral drug)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer.
- What could go wrong
- This was a very early (Phase 1/2) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cabrini Hospital Malvern
Malvern, Victoria, 3144, Australia
-
Calvary Mater Hospital Newcastle
Waratah, New South Wales, 2298, Australia
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Ellison Institute of Technology
Los Angeles, California, 90064, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
New York, New York, 10016, United States
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Macquarie University Hospital
North Ryde, New South Wales, 2109, Australia
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado, 80012, United States
-
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado, 80124, United States
-
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Phone-Based navigation could boost breast cancer detection in kenya
- Can a personalized exercise program boost recovery in cancer survivors?